- 學位論文
新產品「非侵入性治療弱視眼鏡」的商品化可行性之評估研究
A Feasibility Study of Commercialization Assessment- New Product “Eyetronix Flicker Glass”
摘要
根據世界衛生組織的調查報告顯示，全球視覺障礙的人口已達到2.85億，而當中的弱視人口為2.46億，比重占整體人口約4%。弱視是指幼年時期的眼球檢查正常，但視力卻不正常，即使配戴眼鏡進行矯正後，其視力仍無法達到0.8以上，患者多數為幼年人口。 目前市面上治療弱視的方法，各有不同的療程與使用方式；為了改善弱視患者的生活品質與提升治療效率，現已成功研發出「非侵入性治療弱視眼鏡」，配戴此款醫療電子眼鏡及其內建控制器進行目力訓練，不需再搭配其他治療儀器，且在臨床實驗上也已證實其療效。 本研究設計透過三構面「經濟可行性」、「技術可行性」、「消費者接受可行性」進行分析。在「經濟可行性」依據「產值數據」與「通路規劃」兩方面文獻分析；「技術可行性」以「專利申請」與「臨床實驗數據」佐證；「消費者接受可行性」採用科技接受模式，提出5項研究假說並設計問卷，透過統計分析驗證在「消費者接受可行性」上，消費者對產品「易用性」與「有用性」都有高度認知，購買意願也隨之提高。顯示「非侵入性治療弱視眼鏡」在市場上可為消費者接受，對於其商品化的可行性評估具正面態度，因此「非侵入性治療弱視眼鏡」商品化評估之研究結果為可行。
並列摘要
Based on WHO survey, the world Visual Impairment population has reached 285 millions while Amblyopia population is at 246 millions (4% of the world population). The definition of Amblyopia is such that the patient’s eyeball is normal while eyesight is abnormal; after wearing corrective lenses, eyesight maintains visual acuity below 0.8. The primary patient demographic is juvenile. There are varies available treatments in the marketplace, such as eye patches, atropine, etc. However, the effectiveness and compliance of these treatments is low. In order to improve the life quality and efficiency, a non-invasive Amblyopia eyeglass that uses LCD lenses in combining with a preset level of frequency was invented. Thru clinical studies, it has proven to be a highly effective form of therapy. This paper is investigating the commercialization of Eyetronix Flicker Glass thru the following studies: economical feasibility, technical feasibility and consumer acceptance feasibility. Based on the results of research, it is proved the commercialization of new product “Eyetronix Flicker Glass” is feasible.